SS-31 (Elamipretide)
Elamipretide — a mitochondria-targeting peptide that earned a US rare-disease approval after a long clinical program; gray-market versions have nothing to do with that product.
What it is
SS-31, or elamipretide, is the rare gray-market name with a genuine pharmaceutical arc behind it: a mitochondria-targeting tetrapeptide that went through a full clinical development program and earned US approval for Barth syndrome, an ultra-rare genetic disease.
That arc cuts both ways for wellness marketing. Yes, this is real mitochondrial medicine — developed, trialed, approved for a specific devastating condition. No, none of that transfers to 'mitochondrial optimization' vials: the approval belongs to a regulated product for a defined disease, and trials in commoner conditions (heart failure, mitochondrial myopathy) produced mixed results.
What researchers have actually studied it for
Mitochondrial dysfunction across a real clinical program — Barth syndrome (approved), mitochondrial myopathy and heart failure (mixed results).
How it works
Elamipretide concentrates in the inner mitochondrial membrane and binds cardiolipin, stabilizing the membrane architecture that electron transport depends on — improving how damaged mitochondria produce energy and reducing oxidative stress. It's among the first drugs to target the mitochondrial membrane itself.
The molecule itself
A four-amino-acid peptide with alternating aromatic-cationic structure — a Szeto-Schiller peptide — that concentrates a thousandfold in the inner mitochondrial membrane and binds cardiolipin, the membrane's signature lipid. Among the first drugs designed for a membrane rather than a protein target.
Where it came from
Discovered in academic research (the 'Szeto-Schiller' peptides that give SS-31 its name) and developed by Stealth BioTherapeutics through more than a decade of trials — heart failure, mitochondrial myopathy, eye disease, Barth syndrome — the program survived setbacks to reach a US approval for Barth syndrome in 2025.
The timeline
2000s
Szeto-Schiller peptides characterized academically.
2010s
Stealth BioTherapeutics trials span heart failure, mitochondrial myopathy, eye disease.
2019–24
Mixed large-trial results; Barth syndrome data builds through regulatory review cycles.
2025
US approval for Barth syndrome (as Forzinity) — an ultra-rare-disease landmark.
What the research record actually contains
- A real multi-indication clinical program spanning phase 1–3.
- Barth syndrome data supporting its US approval.
- Mixed or negative results in larger indications like heart failure — the honest other half of the record.
What could change this assessment
Genuinely watchable: post-approval data in Barth syndrome, possible label expansion attempts, and the broader cardiolipin-targeting concept it validated. The rare case where the science is ahead of the gray market's imagination.
What's known about risks
Characterized in trials: injection-site reactions lead the profile in studied populations. As always, the approved product's characterization does not extend to research-chemical vials with unverified contents.
Where it stands legally
An approved US drug for its rare-disease indication, prescription-only through legitimate channels; 'SS-31' sold online is an unregulated imitation trading on the name.
Worth asking a licensed provider
- 1.Is my interest a diagnosed mitochondrial condition, or wellness extrapolation?
- 2.If mitochondrial disease is suspected, what specialist work-up applies?
- 3.What separates the approved product from the vials using its name?
Common claims, corrected
“It's approved, so mitochondrial optimization is validated.”
Reality: It's approved for one ultra-rare genetic disease after mixed results elsewhere — including heart-failure trials that missed. The approval validates a disease treatment, not a wellness category.
“Gray-market SS-31 is the same as the drug.”
Reality: The approved product is a regulated pharmaceutical for a defined indication; vials wearing the research name share letters, not oversight.
SS-31 (Elamipretide) FAQ
Is SS-31 the same as elamipretide?
Same molecule — SS-31 is the research name, elamipretide the drug name. The gray market sells the research name; the pharmacy channel dispenses the approved product for its rare-disease indication.
Is elamipretide FDA-approved?
Yes — for Barth syndrome, an ultra-rare genetic disease, after a long development program. That approval doesn't validate wellness use of look-alike vials.
Does SS-31 boost mitochondria in healthy people?
Never tested. Its trials involved diseased mitochondria; 'optimization' in healthy adults is marketing extrapolation from a rare-disease drug.
What is Barth syndrome?
An ultra-rare genetic disorder of cardiolipin metabolism causing heart and muscle disease in boys — precisely the biology elamipretide targets, which is why the approval landed there first.
Why did its heart-failure trials miss?
Common-disease heart failure has many drivers; membrane repair addressed one. The lesson generalizes: mechanism precision predicts rare-disease wins better than broad-disease ones.